Rein Therapeutics Inc.
RNTX
$1.40
-$0.08-5.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 62.24% | -51.32% | -31.72% | -53.56% | 20.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.54% | -23.98% | -22.15% | -20.61% | 207.08% |
| Operating Income | 9.54% | 23.98% | 22.15% | 20.61% | -207.08% |
| Income Before Tax | 4.55% | 23.71% | 22.66% | -479.44% | -220.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.55% | 23.71% | 22.66% | -458.40% | -220.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.55% | 23.71% | 22.66% | -458.40% | -220.03% |
| EBIT | 9.54% | 23.98% | 22.15% | 20.61% | -207.08% |
| EBITDA | 9.54% | 23.96% | 21.73% | 20.04% | -208.96% |
| EPS Basic | 21.56% | 37.21% | 70.70% | -22.77% | 32.91% |
| Normalized Basic EPS | 21.58% | 37.19% | 70.70% | 83.50% | 32.68% |
| EPS Diluted | 21.56% | 37.21% | 70.70% | -22.77% | 32.91% |
| Normalized Diluted EPS | 21.58% | 37.19% | 70.70% | 83.50% | 32.68% |
| Average Basic Shares Outstanding | 21.69% | 21.48% | 163.99% | 354.83% | 377.03% |
| Average Diluted Shares Outstanding | 21.69% | 21.48% | 163.99% | 354.83% | 377.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |